BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); RIPK3 (RIP3); mixed-lineage kinase domain-like (MLKL)

August 4, 2016 7:00 AM UTC

Patient sample and mouse studies suggest inhibiting the necroptosis-related proteins RIPK1, RIPK3 or MLKL could help treat atherosclerosis. Levels of RIPK3 and MLKL were higher in carotid plaque sampl...